Episode Details
Back to Episodes
Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology
Published 10 months ago
Description
CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD.